{ "FullStudy":{ "Rank":217793, "Study":{ "ProtocolSection":{ "IdentificationModule":{ "NCTId":"NCT01516762", "OrgStudyIdInfo":{ "OrgStudyId":"15995" }, "SecondaryIdInfoList":{ "SecondaryIdInfo":[ { "SecondaryId":"2011-004469-33", "SecondaryIdType":"EudraCT Number" } ] }, "Organization":{ "OrgFullName":"Bayer", "OrgClass":"INDUSTRY" }, "BriefTitle":"Radium-223 Dichloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases", "OfficialTitle":"Radium-223 Chloride (BAY88-8223) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone Metastases" }, "StatusModule":{ "StatusVerifiedDate":"July 2014", "OverallStatus":"No longer available", "StudyFirstSubmitDate":"January 20, 2012", "StudyFirstSubmitQCDate":"January 20, 2012", "StudyFirstPostDateStruct":{ "StudyFirstPostDate":"January 25, 2012", "StudyFirstPostDateType":"Estimate" }, "LastUpdateSubmitDate":"July 11, 2014", "LastUpdatePostDateStruct":{ "LastUpdatePostDate":"July 14, 2014", "LastUpdatePostDateType":"Estimate" } }, "SponsorCollaboratorsModule":{ "ResponsibleParty":{ "ResponsiblePartyType":"Sponsor" }, "LeadSponsor":{ "LeadSponsorName":"Bayer", "LeadSponsorClass":"INDUSTRY" } }, "OversightModule":{}, "DescriptionModule":{ "BriefSummary":"This study is a prospective, interventional, open-label, multi-center early access program for the use of Ra-223 Cl2 in HRPC/CRPC patients diagnosed with symptomatic bone metastasis and to collect additional short and long term safety data on the product." }, "ConditionsModule":{ "ConditionList":{ "Condition":[ "Prostatic Neoplasms" ] }, "KeywordList":{ "Keyword":[ "Radium 223", "Alpharadin", "Prostate Cancer", "Bone metastases", "Castrate resistant prostate cancer", "Hormone refractory prostate cancer" ] } }, "DesignModule":{ "StudyType":"Expanded Access" }, "ArmsInterventionsModule":{ "InterventionList":{ "Intervention":[ { "InterventionType":"Drug", "InterventionName":"Radium-223 dichloride (BAY88-8223)", "InterventionDescription":"One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight." } ] } }, "EligibilityModule":{ "EligibilityCriteria":"Inclusion Criteria:\n\nAge ≥ 18 years\nHistologically or cytologically confirmed prostate cancer\nPatients diagnosed with symptomatic progressive bone predominant metastatic CRPC/HRPC with at least 2 skeletal metastases on imaging with no lung, liver, and/or brain metastasis (lymph node only metastasis is allowed)\n\nSymptomatic is defined as either\n\nRegular (not occasional) use of analgesic medication for cancer related bone pain (≥ level 1; World Health Organization [WHO] ladder for cancer pain), or\nTreatment with external beam radiation therapy (EBRT) for bone pain (the EBRT should be within the last 12 weeks before treatment)\n\nProgressive disease is defined either by:\n\nThe appearance of new bone lesions. If progression is based on new lesion(s) on imaging only without an increase in prostate specific antigen (PSA), then PSA values from 3 assessments within the last 6 months must be provided; OR\nIn the absence of new bone lesions, 2 subsequent increases in serum PSA over previous reference value, which should not be more than 6 months before screening, each measured at least 1 week apart with the last PSA ≥ 5 ng/mL. (The reference value time point 1, is defined as the last PSA measured before increases are documented, with subsequent values obtained a minimum of 1 week apart. If the PSA at time point 3 is greater than the PSA at time point 2, then eligibility has been met. If the PSA at time point 3 is not greater than the PSA at time point 2 but, the PSA value at time point 4 and/or time point 5 is greater than the PSA at time point 2, the patient is eligible assuming that other criteria are met).\nNo intention to use cytotoxic chemotherapy within the next 6 months\nLife expectancy ≥ 6 months\nEastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-2\n\nAdequate hematological, liver, and renal function\n\nAbsolute neutrophil count (ANC) ≥ 1.5 x10^9/L\nPlatelet count ≥ 100 x10^9/L\nHemoglobin ≥ 10.0 g/dL (100 g/L; 6.2 mmol/L)\nTotal bilirubin level ≤ 1.5 x institutional upper limit of normal (ULN)\nAspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN\nCreatinine ≤ 1.5 x ULN\nAlbumin > 25 g/L *Any bone imaging techniques as per institutional standard of care\n\nExclusion Criteria:\n\nTreatment with an investigational drug within previous 4 weeks, or planned during the treatment period or follow-up\nEligible for first course of docetaxel, i.e., patients who are fit enough, willing, and who are located where treatment with docetaxel is available\nTreatment with cytotoxic chemotherapy within previous 4 weeks prior to screening, or failure to recover from adverse events (AEs) due to cytotoxic chemotherapy administered more than 4 weeks previous prior to screening (however, ongoing neuropathy is permitted)\nPrior hemibody external radiotherapy is excluded. Patients who received other types of prior external radiotherapy are allowed provided that the bone marrow function is assessed and meets the protocol requirements for hemoglobin, absolute neutrophil count, and platelets\nReceived systemic therapy with radionuclides (e.g., strontium-89, samarium-153, rhenium-186, or rhenium-188, or radium-223 dichloride) for the treatment of bony metastases\nOther malignancy treated within the last 3 years (except non melanoma skin cancer or low-grade superficial bladder cancer)\nVisceral metastases as assessed by abdominal or pelvic computed tomography (CT) (or other imaging modality based on institutional standard of care)\nPresence of brain metastases\nLymphadenopathy exceeding 6 cm in short-axis diameter\nAny size pelvic lymphadenopathy if it is thought to be a contributor to concurrent hydronephrosis.\nImminent spinal cord compression based on clinical findings and/or magnetic resonance imaging (MRI). Patients with history of spinal cord compression should have completely recovered.\n\nAny other serious illness or medical condition, such as but not limited to:\n\nAny infection ≥ National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 Grade 2\nCardiac Failure New York Heart Association (NYHA) Class III or IV\nCrohn's disease or ulcerative colitis\nBone marrow dysplasia\nFecal incontinence", "Gender":"Male", "MinimumAge":"18 Years", "StdAgeList":{ "StdAge":[ "Adult", "Older Adult" ] } }, "ContactsLocationsModule":{ "OverallOfficialList":{ "OverallOfficial":[ { "OverallOfficialName":"Bayer Study Director", "OverallOfficialAffiliation":"Bayer", "OverallOfficialRole":"Study Director" } ] }, "LocationList":{ "Location":[ { "LocationCity":"Birmingham", "LocationState":"Alabama", "LocationZip":"35233", "LocationCountry":"United States" },{ "LocationCity":"Phoenix", "LocationState":"Arizona", "LocationZip":"85040", "LocationCountry":"United States" },{ "LocationCity":"Scottsdale", "LocationState":"Arizona", "LocationZip":"85260", "LocationCountry":"United States" },{ "LocationCity":"Greenbrae", "LocationState":"California", "LocationZip":"94904", "LocationCountry":"United States" },{ "LocationCity":"La Jolla", "LocationState":"California", "LocationZip":"92093", "LocationCountry":"United States" },{ "LocationCity":"San Francisco", "LocationState":"California", "LocationZip":"94143", "LocationCountry":"United States" },{ "LocationCity":"Stanford", "LocationState":"California", "LocationZip":"94305", "LocationCountry":"United States" },{ "LocationCity":"Aurora", "LocationState":"Colorado", "LocationZip":"80045", "LocationCountry":"United States" },{ "LocationCity":"Newark", "LocationState":"Delaware", "LocationZip":"19718", "LocationCountry":"United States" },{ "LocationCity":"Washington", "LocationState":"District of Columbia", "LocationZip":"20007", "LocationCountry":"United States" },{ "LocationCity":"Washington", "LocationState":"District of Columbia", "LocationZip":"20060", "LocationCountry":"United States" },{ "LocationCity":"Fort Myers", "LocationState":"Florida", "LocationZip":"33901", "LocationCountry":"United States" },{ "LocationCity":"Miami Beach", "LocationState":"Florida", "LocationZip":"33140", "LocationCountry":"United States" },{ "LocationCity":"Tampa", "LocationState":"Florida", "LocationZip":"33612", "LocationCountry":"United States" },{ "LocationCity":"Atlanta", "LocationState":"Georgia", "LocationZip":"30322", "LocationCountry":"United States" },{ "LocationCity":"Honolulu", "LocationState":"Hawaii", "LocationZip":"96813-2413", "LocationCountry":"United States" },{ "LocationCity":"Goshen", "LocationState":"Indiana", "LocationZip":"46526", "LocationCountry":"United States" },{ "LocationCity":"Iowa City", "LocationState":"Iowa", "LocationZip":"52242", "LocationCountry":"United States" },{ "LocationCity":"New Orleans", "LocationState":"Louisiana", "LocationZip":"70112", "LocationCountry":"United States" },{ "LocationCity":"Shreveport", "LocationState":"Louisiana", "LocationZip":"71103", "LocationCountry":"United States" },{ "LocationCity":"Baltimore", "LocationState":"Maryland", "LocationZip":"21201-1595", "LocationCountry":"United States" },{ "LocationCity":"Baltimore", "LocationState":"Maryland", "LocationZip":"21229", "LocationCountry":"United States" },{ "LocationCity":"Baltimore", "LocationState":"Maryland", "LocationZip":"21287", "LocationCountry":"United States" },{ "LocationCity":"Bethesda", "LocationState":"Maryland", "LocationZip":"20889", "LocationCountry":"United States" },{ "LocationCity":"Rockville", "LocationState":"Maryland", "LocationZip":"20850", "LocationCountry":"United States" },{ "LocationCity":"Boston", "LocationState":"Massachusetts", "LocationZip":"02114", "LocationCountry":"United States" },{ "LocationCity":"Boston", "LocationState":"Massachusetts", "LocationZip":"02215", "LocationCountry":"United States" },{ "LocationCity":"Ann Arbor", "LocationState":"Michigan", "LocationZip":"48109-0028", "LocationCountry":"United States" },{ "LocationCity":"Detroit", "LocationState":"Michigan", "LocationZip":"48201", "LocationCountry":"United States" },{ "LocationCity":"Detroit", "LocationState":"Michigan", "LocationZip":"48202", "LocationCountry":"United States" },{ "LocationCity":"Minneapolis", "LocationState":"Minnesota", "LocationZip":"55455", "LocationCountry":"United States" },{ "LocationCity":"St. Louis", "LocationState":"Missouri", "LocationZip":"63110", "LocationCountry":"United States" },{ "LocationCity":"Las Vegas", "LocationState":"Nevada", "LocationZip":"89169", "LocationCountry":"United States" },{ "LocationCity":"New Brunswick", "LocationState":"New Jersey", "LocationZip":"08903-2681", "LocationCountry":"United States" },{ "LocationCity":"Newark", "LocationState":"New Jersey", "LocationZip":"07103", "LocationCountry":"United States" },{ "LocationCity":"New Hyde Park", "LocationState":"New York", "LocationZip":"11040-1496", "LocationCountry":"United States" },{ "LocationCity":"New York", "LocationState":"New York", "LocationZip":"10016", "LocationCountry":"United States" },{ "LocationCity":"New York", "LocationState":"New York", "LocationZip":"10065", "LocationCountry":"United States" },{ "LocationCity":"Syracuse", "LocationState":"New York", "LocationZip":"13210", "LocationCountry":"United States" },{ "LocationCity":"Durham", "LocationState":"North Carolina", "LocationZip":"27710", "LocationCountry":"United States" },{ "LocationCity":"Raleigh", "LocationState":"North Carolina", "LocationZip":"27607", "LocationCountry":"United States" },{ "LocationCity":"Cleveland", "LocationState":"Ohio", "LocationZip":"44195", "LocationCountry":"United States" },{ "LocationCity":"Columbus", "LocationState":"Ohio", "LocationZip":"43212", "LocationCountry":"United States" },{ "LocationCity":"Springfield", "LocationState":"Oregon", "LocationZip":"97477", "LocationCountry":"United States" },{ "LocationCity":"Philadelphia", "LocationState":"Pennsylvania", "LocationZip":"19107", "LocationCountry":"United States" },{ "LocationCity":"Philadelphia", "LocationState":"Pennsylvania", "LocationZip":"19111-2497", "LocationCountry":"United States" },{ "LocationCity":"Philadelphia", "LocationState":"Pennsylvania", "LocationZip":"19401", "LocationCountry":"United States" },{ "LocationCity":"Pittsburgh", "LocationState":"Pennsylvania", "LocationZip":"15213", "LocationCountry":"United States" },{ "LocationCity":"Myrtle Beach", "LocationState":"South Carolina", "LocationZip":"29572", "LocationCountry":"United States" },{ "LocationCity":"Myrtle Beach", "LocationState":"South Carolina", "LocationZip":"29577", "LocationCountry":"United States" },{ "LocationCity":"Nashville", "LocationState":"Tennessee", "LocationZip":"37232", "LocationCountry":"United States" },{ "LocationCity":"Houston", "LocationState":"Texas", "LocationZip":"77030", "LocationCountry":"United States" },{ "LocationCity":"Plano", "LocationState":"Texas", "LocationZip":"75093", "LocationCountry":"United States" },{ "LocationCity":"San Antonio", "LocationState":"Texas", "LocationZip":"78229", "LocationCountry":"United States" },{ "LocationCity":"Temple", "LocationState":"Texas", "LocationZip":"76508", "LocationCountry":"United States" },{ "LocationCity":"Hampton", "LocationState":"Virginia", "LocationZip":"23666", "LocationCountry":"United States" },{ "LocationCity":"Norfolk", "LocationState":"Virginia", "LocationZip":"23507", "LocationCountry":"United States" },{ "LocationCity":"Seattle", "LocationState":"Washington", "LocationZip":"98122", "LocationCountry":"United States" },{ "LocationCity":"Wheeling", "LocationState":"West Virginia", "LocationZip":"26003", "LocationCountry":"United States" },{ "LocationCity":"Milwaukee", "LocationState":"Wisconsin", "LocationZip":"53226-3596", "LocationCountry":"United States" } ] } } }, "DerivedSection":{ "MiscInfoModule":{ "VersionHolder":"April 22, 2020" }, "InterventionBrowseModule":{ "InterventionMeshList":{ "InterventionMesh":[ { "InterventionMeshId":"C000581106", "InterventionMeshTerm":"Radium Ra 223 dichloride" } ] }, "InterventionAncestorList":{ "InterventionAncestor":[ { "InterventionAncestorId":"D000000970", "InterventionAncestorTerm":"Antineoplastic Agents" } ] }, "InterventionBrowseLeafList":{ "InterventionBrowseLeaf":[ { "InterventionBrowseLeafId":"M255633", "InterventionBrowseLeafName":"Radium Ra 223 dichloride", "InterventionBrowseLeafAsFound":"Radium-223 dichloride", "InterventionBrowseLeafRelevance":"high" } ] }, "InterventionBrowseBranchList":{ "InterventionBrowseBranch":[ { "InterventionBrowseBranchAbbrev":"ANeo", "InterventionBrowseBranchName":"Antineoplastic Agents" },{ "InterventionBrowseBranchAbbrev":"All", "InterventionBrowseBranchName":"All Drugs and Chemicals" } ] } }, "ConditionBrowseModule":{ "ConditionMeshList":{ "ConditionMesh":[ { "ConditionMeshId":"D000011471", "ConditionMeshTerm":"Prostatic Neoplasms" },{ "ConditionMeshId":"D000009362", "ConditionMeshTerm":"Neoplasm Metastasis" } ] }, "ConditionAncestorList":{ "ConditionAncestor":[ { "ConditionAncestorId":"D000005834", "ConditionAncestorTerm":"Genital Neoplasms, Male" },{ "ConditionAncestorId":"D000014565", "ConditionAncestorTerm":"Urogenital Neoplasms" },{ "ConditionAncestorId":"D000009371", "ConditionAncestorTerm":"Neoplasms by Site" },{ "ConditionAncestorId":"D000009369", "ConditionAncestorTerm":"Neoplasms" },{ "ConditionAncestorId":"D000005832", "ConditionAncestorTerm":"Genital Diseases, Male" },{ "ConditionAncestorId":"D000011469", "ConditionAncestorTerm":"Prostatic Diseases" },{ "ConditionAncestorId":"D000009385", "ConditionAncestorTerm":"Neoplastic Processes" },{ "ConditionAncestorId":"D000010335", "ConditionAncestorTerm":"Pathologic Processes" } ] }, "ConditionBrowseLeafList":{ "ConditionBrowseLeaf":[ { "ConditionBrowseLeafId":"M12918", "ConditionBrowseLeafName":"Prostatic Neoplasms", "ConditionBrowseLeafAsFound":"Prostatic Neoplasms", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M10890", "ConditionBrowseLeafName":"Neoplasm Metastasis", "ConditionBrowseLeafAsFound":"Metastases", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M7529", "ConditionBrowseLeafName":"Genital Neoplasms, Male", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M15898", "ConditionBrowseLeafName":"Urogenital Neoplasms", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M7527", "ConditionBrowseLeafName":"Genital Diseases, Male", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M12916", "ConditionBrowseLeafName":"Prostatic Diseases", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M10913", "ConditionBrowseLeafName":"Neoplastic Processes", "ConditionBrowseLeafRelevance":"low" } ] }, "ConditionBrowseBranchList":{ "ConditionBrowseBranch":[ { "ConditionBrowseBranchAbbrev":"BC04", "ConditionBrowseBranchName":"Cancers and Other Neoplasms" },{ "ConditionBrowseBranchAbbrev":"BXS", "ConditionBrowseBranchName":"Urinary Tract, Sexual Organs, and Pregnancy Conditions" },{ "ConditionBrowseBranchAbbrev":"All", "ConditionBrowseBranchName":"All Conditions" },{ "ConditionBrowseBranchAbbrev":"BC23", "ConditionBrowseBranchName":"Symptoms and General Pathology" } ] } } } } } }